These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7750887)

  • 1. [Innovative approaches in therapy of chronic polyarthritis].
    Keysser G; Burmester GR
    Fortschr Med; 1995 Mar; 113(7):77-80. PubMed ID: 7750887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?].
    Fenner H
    Z Rheumatol; 1995; 54(3):158-64. PubMed ID: 7660686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.
    Patten C; Bush K; Rioja I; Morgan R; Wooley P; Trill J; Life P
    Arthritis Rheum; 2004 Oct; 50(10):3334-45. PubMed ID: 15476226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF inhibitors in the treatment of arthritis.
    Lorenz HM
    Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.
    Ferraccioli G; Gremese E
    Autoimmun Rev; 2004 Jun; 3(4):261-6. PubMed ID: 15246021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental therapy of rheumatoid arthritis with cytokine antagonists].
    Manger B
    Z Rheumatol; 1995; 54(2):105-9. PubMed ID: 7793156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New immunologic treatment of rheumatoid arthritis].
    Sany J
    Rev Rhum Ed Fr; 1993 Mar; 60(3):229-39. PubMed ID: 8293009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
    Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
    Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R; Shealy D
    Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
    Charles P; Elliott MJ; Davis D; Potter A; Kalden JR; Antoni C; Breedveld FC; Smolen JS; Eberl G; deWoody K; Feldmann M; Maini RN
    J Immunol; 1999 Aug; 163(3):1521-8. PubMed ID: 10415055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines].
    Lukina GV; Sigidin IaA; Skurkovich SV; Skurkovich BS
    Ter Arkh; 1998; 70(5):32-7. PubMed ID: 9644739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy in rheumatoid arthritis; current status].
    Breedveld FC; van de Putte LB
    Ned Tijdschr Geneeskd; 1996 Jun; 140(24):1255-9. PubMed ID: 8700279
    [No Abstract]   [Full Text] [Related]  

  • 16. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF-alpha therapy as a new option in treatment of rheumatoid arthritis?].
    Leeb BF; Sautner J
    Wien Med Wochenschr; 1999; 149(19-20):554-7. PubMed ID: 10637966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.
    Herman S; Krönke G; Schett G
    Trends Mol Med; 2008 Jun; 14(6):245-53. PubMed ID: 18468489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological therapies for rheumatoid arthritis.
    Edwards CJ
    Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.